ZBH

#613
Zimmer Biomet Holdings, Inc. Common Stock
100.0 1 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
99.96
100.29
Intervallo Annuale
79.12
103.69
Variazione giornaliera
-0.90%
Variazione Mensile
+4.12%
Variazione di 6 mesi
+3.25%
Variazione Annuale
-3.37%
Chiusura Precedente
100.9 2
Open
100.0 0
Minimo
99.9 6
Massimo
100.2 9
Volume
581
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ZIMMER BIOMET HOLDINGS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q1 FY2026
8-K

ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2016

Full document

Business Context and Reporting Period

This Form 8-K filing by Zimmer Biomet Holdings, Inc. reports on events occurring at the Company's annual meeting of stockholders held on May 3, 2016. The report details the ratification of corporate governance actions, including the election of directors, the appointment of auditors, executive compensation approval, and amendments to the stock incentive plan.

Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting results.

Material Changes

The primary material change reported is the approval of amendments to the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan. Key changes include:

  • An increase of 10.0 million shares available for issuance under the plan.
  • An extension of the plan term to May 31, 2024.

Guidance, Outlook, and Voting Results

Stockholders approved four proposals at the annual meeting. The vote tabulations were as follows:

  • Election of Directors: All 12 nominees were elected. Votes ranged from approximately 154.6 million "For" to 157.4 million "For" per nominee, with "Against" votes ranging from 424,418 to 2,337,253.
  • Ratification of Auditor: PricewaterhouseCoopers LLP was ratified with 172,571,481 votes "For" and 1,676,857 "Against."
  • Executive Compensation (Say-on-Pay): Approved on an advisory basis with 128,088,629 votes "For" and 28,773,972 "Against."
  • Amended 2009 Stock Incentive Plan: Approved with 144,007,076 votes "For" and 13,052,463 "Against."

The filing does not provide management commentary on future financial guidance, risks, or contingencies beyond the standard incorporation of the proxy statement by reference.

Key Facts for Investor Verification

  • Verify the total number of shares outstanding to assess the dilution impact of the 10.0 million share increase in the stock incentive plan.
  • Review the full text of the amended 2009 Plan (Exhibit 10.1) for specific terms regarding vesting and eligibility.
  • Note the significant "Against" vote count (approx. 28.8 million) on the executive compensation proposal, which may indicate shareholder sentiment regarding pay practices.
  • Confirm the re-election of all 12 directors, noting that Larry C. Glasscock received the highest number of "Against" votes (2,337,253).

Notizie